A 61-year-old man with a history of hypertension, smoking, and hyperlipoproteinemia presented to our chest pain unit with typical angina. An electrocardiogram showed ST-segment elevation in the anterior leads, and emergency coronary angiography demonstrated the presence of a ruptured plaque in the proximal left anterior descending coronary artery. The vessel was almost entirely occluded by an intraluminal thrombus (Fig. 1A) . The lesion was dilated with a 2.75 Â 15-mm balloon (Maverick, Boston Scientific, Natick, 
electrocardiogram showed ST-segment elevation in the anterior leads, and emergency coronary angiography demonstrated the presence of a ruptured plaque in the proximal left anterior descending coronary artery. The vessel was almost entirely occluded by an intraluminal thrombus (Fig. 1A) . The lesion was dilated with a 2.75 Â 15-mm balloon (Maverick, Boston Scientific, Natick, Massachusetts) and a 3 Â 18-mm coronary bioresorbable scaffold (Absorb, Abbott Vascular, Abbott Park, Illinois) was implanted with a good result (Fig. 1B) .
One year later, control angiography demonstrated complete patency of the scaffold (Fig. 1C) . Optical coherence tomography (LightLab C-7, St. Jude Medical, St. Paul, Minnesota) showed a good apposition and dilation of the struts. The previously ruptured plaque was covered by a 130-to 150-mm layer of fibrous neointima (Fig. 1D ). Both acetylcholine (Miochol E, Bausch and Lomb, Rochester, New York) administered in 3 escalating doses for 3 min each through a microcatheter placed in the proximal left anterior descending artery and nitroglycerin 200 mg caused a dosedependent coronary vasodilation in the scaffolded segment (Figs. 1E to 1I) .
Data on the outcome of unstable plaques treated with bioresorbable scaffolds are currently not available. We provide evidence in support of the concept that, after initial mechanical stabilization with a bioresorbable scaffold, biological processes lead to anatomic and physiological improvement of unstable plaques. A moderate neointimal growth after interventional treatment might in this setting limit the risk of future exposure of thrombogenic tissues, thus stabilizing the plaque; similarly, effective vasodilation in response to acetylcholine reflects an improved endothelial function. Once these processes have occurred, a permanent metal implant might thus be unnecessary. Temporary plaque "sealing" with a bioresorbable scaffold should be evaluated as an alternative to metal stents in the setting of unstable plaques.
